{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T06:43:25.944467+00:00","company":{"ticker":"CRVO","cik":1053691,"company_name":"CervoMed Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"e4504a705d","cik":1053691,"ticker":"CRVO","company_name":"CervoMed Inc.","filed_at":"2024-05-20T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"routine","effective_date":"2024-05-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"William Elder","successor_named":true},"claim":"William Tanner was terminated as Chief Financial Officer at CervoMed Inc..","evidence_excerpt":"Dr. Tanner’s employment with the Company will terminate effective May 31, 2024, and, effective June 1, 2024, Dr. Tanner will begin service as a consultant to the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-017648","anchor_url":"https://secwatch.observer/filing/0001437749-24-017648#claim-e4504a705d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/0001437749-24-017648-index.htm"},{"fact_type":"executive_change","fact_key":"babb346485","cik":1053691,"ticker":"CRVO","company_name":"CervoMed Inc.","filed_at":"2024-05-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"William Elder was appointed as Chief Financial Officer at CervoMed Inc..","evidence_excerpt":"appointed William Elder, the Company’s current General Counsel, Corporate Secretary and Acting Principal Financial Officer, to serve as the Company’s Chief Financial Officer, effective June 1, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-017648","anchor_url":"https://secwatch.observer/filing/0001437749-24-017648#claim-babb346485","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017648/0001437749-24-017648-index.htm"},{"fact_type":"earnings_release","fact_key":"790ad0941c169404fa9cc36a59f6b2fa48e6de16","cik":1053691,"ticker":"CRVO","company_name":"CervoMed Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"approximately $2.5 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.","evidence_excerpt":"Net income was approximately $2.5 million for the three months ended March 31, 2024","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-017132","anchor_url":"https://secwatch.observer/filing/0001437749-24-017132#claim-790ad0941c169404fa9cc36a59f6b2fa48e6de16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924017132/0001437749-24-017132-index.htm"},{"fact_type":"earnings_release","fact_key":"dd3f25f43733f55d6cf17baa1cd10da8d51398e4","cik":1053691,"ticker":"CRVO","company_name":"CervoMed Inc.","filed_at":"2024-04-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2023","report_date":"2024-04-01","result_type":"reported_results","revenue_text":null},"claim":"CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-011212","anchor_url":"https://secwatch.observer/filing/0001437749-24-011212#claim-dd3f25f43733f55d6cf17baa1cd10da8d51398e4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924011212/0001437749-24-011212-index.htm"},{"fact_type":"material_agreement","fact_key":"d64f9530b1bee6087636f23a9894e0e308114086","cik":1053691,"ticker":"CRVO","company_name":"CervoMed Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"purchasers named therein","effective_date":"2024-03-28","item_codes_triggered":["1.01"],"value_text":"approximately $50 million"},"claim":"CervoMed Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $50 million (effective 2024-03-28).","evidence_excerpt":"On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-24-009697","anchor_url":"https://secwatch.observer/filing/0001437749-24-009697#claim-d64f9530b1bee6087636f23a9894e0e308114086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/0001437749-24-009697-index.htm"}]}